Related Experiment Video
Updated: Jan 28, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
Resistance to bortezomib in breast cancer cells that downregulate Bim through FOXA1 O-GlcNAcylation
Yubo Liu1, Xue Wang1, Tong Zhu1
1Department of Biochemistry, School of Life Science & Medicine, Dalian University of Technology, Panjin, China.
Abstract:
Bortezomib (BTZ), a well-established proteasome inhibitor used in the clinical therapy, leads the modulation of several biological alterations and in turn induces apoptosis. Although clinical trials with BTZ have shown promising results for some types of cancers, but not for some others, including those of the breast. The molecular basis of BTZ resistance in breast cancer remains elusive. In the present study, we found that cellular O-GlcNAc modification was dramatically elevated by BTZ treatment in intrinsic resistant MCF-7 and T47D cells, but not in sensitive MDA-MB-231 cells. A progressive increase in O-GlcNAcylation characterized the increased acquired resistance of MDA-MB-231-derived cells. We showed that elevated O-GlcNAc subsequently modified breast cancer related pioneer factor FOXA1 and reduced its protein stability. Further, we demonstrated that FOXA1 attenuation was involved in transcriptional downregulation of proapoptotic Bim and thus suppressed breast cancer cell apoptosis. Finally, the combination of O-GlcNAc inhibitor L01 to BTZ sensitized resistant cells. Our results have revealed a new regulatory mechanism that involves O-GlcNAc elevation mediated Bim deficiency, which plays a key role in the apoptotic dysregulation and BTZ resistance in breast cancer cells.
Insights
Bortezomib resistance in breast cancer is linked to elevated O-GlcNAc modification, which reduces the stability of FOXA1 and suppresses apoptosis. Combining Bortezomib with an O-GlcNAc inhibitor can overcome this resistance.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Bortezomib (BTZ) is a proteasome inhibitor used in cancer therapy, but its efficacy varies across cancer types, with limited success in breast cancer.
- The mechanisms underlying Bortezomib resistance in breast cancer are not fully understood, hindering effective treatment strategies.
Purpose of the Study:
- To elucidate the molecular mechanisms of Bortezomib resistance in breast cancer cells.
- To investigate the role of O-GlcNAc modification in Bortezomib resistance.
- To identify potential therapeutic strategies to overcome Bortezomib resistance.
Main Methods:
- Treatment of breast cancer cell lines (MCF-7, T47D, MDA-MB-231) with Bortezomib.
- Assessment of cellular O-GlcNAc modification levels.
- Analysis of pioneer factor FOXA1 protein stability and its interaction with O-GlcNAc.
- Evaluation of Bim gene expression and its role in apoptosis.
- Combination therapy using Bortezomib and an O-GlcNAc inhibitor (L01).
Main Results:
- Bortezomib treatment significantly increased O-GlcNAc modification in resistant breast cancer cells (MCF-7, T47D) but not in sensitive cells (MDA-MB-231).
- Acquired Bortezomib resistance in MDA-MB-231 cells correlated with increased O-GlcNAcylation.
- Elevated O-GlcNAc reduced FOXA1 protein stability, leading to transcriptional downregulation of the proapoptotic gene Bim.
- This Bim deficiency suppressed Bortezomib-induced apoptosis in resistant breast cancer cells.
- Co-treatment with Bortezomib and the O-GlcNAc inhibitor L01 sensitized resistant cells to Bortezomib.
Conclusions:
- Elevated O-GlcNAc modification is a key mechanism contributing to Bortezomib resistance in breast cancer.
- The O-GlcNAc/FOXA1/Bim pathway regulates apoptosis and Bortezomib sensitivity.
- Combining Bortezomib with O-GlcNAc inhibitors represents a promising therapeutic strategy to overcome Bortezomib resistance in breast cancer.
Related Concept Videos
Treatment Resistant Cancers
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Resistivity
Resistance
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...

